- A small randomised trial found that time-restricted feeding, eating within an 8-hour daily window, reduced Crohn’s disease activity and lowered markers of inflammation over 12 weeks in adults with overweight or obesity.
- Participants using time-restricted feeding also lost weight and reduced visceral fat, despite not being told to cut calories.
- Larger studies are needed to confirm long-term safety and effectiveness.
Intermittent fasting is often discussed as a weight-loss strategy, but researchers are increasingly interested in whether meal timing can influence inflammation and immune function.
A new randomised controlled trial suggests that time-restricted feeding – a form of intermittent fasting where people eat within a set daily window – may reduce Crohn’s disease activity in adults living with overweight or obesity.
In time-restricted feeding (TRF), participants eat all meals within an 8-hour period and fast for the remaining 16 hours each day.
In this 12-week trial, 35 adults with Crohn’s disease and overweight or obesity were randomly assigned to TRF (20 people) or to continue their usual eating pattern (15 people).
Researchers assessed Crohn’s disease activity, abdominal symptoms, inflammation markers, and body composition at baseline and after 12 weeks.
The results showed meaningful improvements in the TRF group.
Symptomatic Crohn’s disease activity fell by around 40% compared with controls, and abdominal discomfort dropped by about 50% over the study period. Participants following TRF also lost approximately 5.5 pounds on average, while those in the control group gained around 3.7 pounds.
Beyond symptoms and weight, the study found changes in blood markers linked to inflammation and metabolic health.
People in the TRF group showed lower levels of leptin and PAI-1, markers that can be associated with inflammation and cardiometabolic risk.
The researchers also reported a marked reduction in harmful visceral fat in the TRF group.
One of the more intriguing claims from the trial is that the benefits were not simply due to eating less or improving diet quality.
The study reports that both groups ate similar foods and amounts overall, suggesting that the timing of intake itself may have contributed to improvements in inflammation and disease activity.
The proposed explanation is biological plausibility rather than certainty.
Meal timing can influence circadian rhythms, gut microbiota, metabolic signalling, and immune responses. Changes in the gut environment and systemic inflammation could, in theory, affect Crohn’s disease activity. The study also reported promising shifts in gut bacteria, although this remains an emerging area with many unanswered questions.
As always, it is important to match enthusiasm with caution. This was a small trial with a short follow-up, so it cannot establish long-term outcomes or rare side effects.
People with inflammatory bowel disease can have complex nutritional needs, and prolonged fasting patterns may not be appropriate for everyone, particularly those at risk of malnutrition or with fluctuating symptoms.
For readers living with diabetes, the idea of fasting can raise additional considerations around blood glucose and medication timing.
Anyone considering time-restricted eating alongside Crohn’s disease or diabetes should discuss it with their clinical team, especially if they use insulin or sulfonylureas.
The study is a promising signal that “when we eat” may matter, but it is not a blanket prescription for all patients.
